肝内胆管癌根治性切除术后生存因素分析及列线图的建立

doi:10.6040/j.issn.1671-7554.0.2020.1548

摘要/Abstract

摘要： 目的探讨肝内胆管癌(ICC)根治性切除术后生存影响因素,个体化建立列线图预测术后总生存时间。方法搜集2009年7月至2017年10月于我院行根治性手术的79例ICC患者的临床及病理资料,Kaplan-Meier和Cox回归模型用于分析临床及病理特征对术后总体生存率和无复发生存率的影响,通过R软件(版本号4.0.1)建立生存列线图,并使用一致性指数、校准曲线及ROC曲线下面积(AUC)验证列线图的预测效能。结果 79例患者术后第1、2、3年累积无复发生存率分别为43.0%、26.6%、20.3%,中位生存期为15个月,79例患者术后第1、2、3年累积总生存率分别为63.3%、41.8%、27.8%。多因素分析显示CA19-9、脉管癌栓、肿瘤数目是影响患者生存的独立危险因素。CA19-9、肿瘤数目、病理分化程度是影响复发的独立危险因素。一致性指数为0.723(95%CI:0.66~0.79),第1、2、3年生存率的AUC分别为0.78(95%CI:0.68~0.89)、0.85(95%CI:0.77~0.93)、0.77(95%CI:0.67~0.87)。结论 ICC预后较差,早期症状不典型,术后生存率低,CA19-9、肿瘤数目是影响生存和复发的共同独立危险因素。经内部验证的列线图对术后患者的生存率有较好的预测能力。

关键词: 肝内胆管癌, 生存分析, 预后因素, 列线图, 复发

Abstract: Objective To explore the prognostic factors after radical resection of intrahepatic cholangiocarcinoma(ICC)and to establish a nomogram to predict postoperative overall survival. Methods The clinicopathological data of 79 ICC patients who underwent radical resection in our hospital during Jul. 2009 and Oct. 2017 were collected. The impacts of clinicopathological characteristics on overall survival and recurrence-free survival were analyzed with Kaplan-Meier and Cox regression models. A survival nomogram was established with R software(version 4.0.1), and the predictive performance of the nomogram was verified with C-index, calibration curve and area under ROC curve(AUC). Results The 1-year, 2-year, and 3-year cumulative recurrence-free survival rates were 43.0%, 26.6% and 20.3%, respectively. The median survival time was 15 months, and the 1-year, 2-year, and 3-year cumulative overall survival rates were 63.3%, 41.8% and 27.8%, respectively. Multivariate analysis demonstrated that CA19-9, lymphovascular invasion and multiple tumors were independent risk factors of overall survival. CA19-9, multiple tumors and differentiation of tumors were independent risk factors of recurrence. The C-index was 0.723(95%CI: 0.66-0.79), and the AUC of 1-year, 2-year, and 3-year survival rates were 0.78(95%CI: 0.68-0.89), 0.85(95%CI: 0.77-0.93), and 0.77(95%CI: 0.67-0.87), respectively. Conclusion ICC has a poor prognosis and low postoperative survival rate. The early symptoms are atypical. CA19-9 and multiple tumors are independent risk factors for both survival and recurrence. The internally validated nomogram can predict the survival rates.

Key words: Intrahepatic cholangiocarcinoma, Survival analysis, Prognostic factors, Nomogram, Recurrence

中图分类号:

R735.8

谢同辉,陈志强,常建华,赵丹文,徐博文,智绪亭. 肝内胆管癌根治性切除术后生存因素分析及列线图的建立[J]. 山东大学学报 (医学版), 2021, 59(4): 93-99.

XIE Tonghui, CHEN Zhiqiang, CHANG Jianhua, ZHAO Danwen, XU Bowen, ZHI Xuting. Analysis of prognostic factors after radical resection of intrahepatic cholangiocarcinoma and establishment of a nomogram[J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 93-99.

参考文献

[1] Gupta A, Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma[J]. Hepatobiliary Surg Nutr, 2017, 6(2): 101-104.
[2] Zhang H, Yang T, Wu M, et al. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management[J]. Cancer Lett, 2016, 379(2): 198-205.
[3] Chun Y, Javle M. Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017, 24(3): 1-7.
[4] Rahnemai-Azar A, Weisbrod A, Dillhoff M, et al. Intrahepatic cholangiocarcinoma: current management and emerging therapies[J]. Expert Rev Gastroenterol Hepatol, 2017, 11(5): 439-449.
[5] 刘连新, 尹大龙. 肝内胆管癌多学科综合治疗优化选择[J]. 中国实用外科杂志, 2020, 40(6): 680-684. LIU Xinlian, YIN Dalong. Optimal management of multidisciplinary treatment for intrahepatic chaolangiocarcinoma[J]. Chinese Journal of Practical Surgery, 2020, 40(6): 680-684.
[6] Mavros M, Economopoulos K, Alexiou V, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis[J]. JAMA Surgery, 2014, 149(6): 565-574.
[7] Van Dyke A, Shiels M, Jones G, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013[J]. Cancer, 2019, 125(9): 1489-1498.
[8] de Jong M, Nathan H, Sotiropoulos G, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment J]. J Clin Oncol, 2011, 29(23): 3140-3145.
[9] Ejaz A, Cloyd J, Pawlik T. Advances in the diagnosis and treatment of patients with intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2020, 27(2): 552-560.
[10] Nathan H, Pawlik T, Wolfgang C, et al. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis[J]. J Gastrointest Surg, 2007, 11(11): 1488-1496; discussion 1496-1497.
[11] Ribero D, Pinna A, Guglielmi A, et al. Surgical approach for long-term srvival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients[J]. Arch Surg, 2012, 147(12): 1107-1113.
[12] Nathan H, Aloia T, Vauthey J, et al. A proposed staging system for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2009, 16(1): 14-22.
[13] Spolverato G, Vitale A, Cucchetti A, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?[J]. Cancer, 2015, 121(22): 3998-4006.
[14] Chan K, Tsai C, Yeh C, et al. Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence[J]. BMC Gastroenterol, 2018, 18(1): 180.
[15] 季鸿翔, 司马辉, 匡悦, 等. 肝内胆管癌根治性切除术中淋巴结清扫价值研究[J]. 中国实用外科杂志, 2020, 40(6): 703-709. JI Hongxiang, SI Mahui, KUANG Yue, et al. Significance of lymphadenectomy in intrahepatic cholangiocarcinoma with radical resection[J]. Chinese Journal of Practical Surgery, 2020, 40(6): 703-709.
[16] Spolverato G, Ejaz A, Kim Y, et al. Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2014, 18(7): 1284-1291.
[17] Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies[J]. Somatic cell genetics, 1979, 5(6): 957-971.
[18] Liang B, Zhong L, He Q, et al. Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis[J]. Med Sci Monit, 2015, 21: 3555-3563. doi: 10.12659/msm.895040.
[19] Yamada T, Nakanishi Y, Okamura K, et al. Impact of serum carbohydrate antigen 19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma[J]. J Gastroenterol Hepatol, 2018, 33(9): 1626-1633.
[20] Bergquist J, Ivanics T, Storlie C, et al. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis[J]. J Surg Oncol, 2016, 114(4): 475-482.
[21] Yang H, Wang J, Li Z, et al. Risk factors and outcomes of early relapse after curative resection of intrahepatic cholangiocarcinoma[J]. Front Oncol, 2019, 9: 854. doi: 10.3389/fonc.2019.00854.
[22] Addeo P, Jedidi I, Locicero A, et al. Prognostic impact of tumor multinodularity in intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2019, 23(9): 1801-1809.
[23] Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience[J]. JAMA Surgery, 2014, 149(5): 432-438.
[24] Okubo S, Mitsunaga S, Kato Y, et al. The prognostic impact of differentiation at the invasive front of biliary tract cancer[J]. J Surg Oncol, 2018, 117(6): 1278-1287.
[25] Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J]. J Clin Oncol, 2013, 31(9): 1188-1195.

相关文章 15

[1]	张莹王宏伟王慧陈福琴. Graves病复发患者外周血中转化生长因子β1水平的变化[J]. 山东大学学报(医学版), 2209, 47(6): 80-.
[2]	陆晨琳,许露,杨俊发,潘华琴,倪清涛. 基于动态列线图及机器学习的慢性阻塞性肺疾病急性加重期伴发肺性脑病风险预测模型构建及验证[J]. 山东大学学报 (医学版), 2026, 64(3): 108-115.
[3]	逄锦宏,苏萍,乔俊鹏,陈巧巧,陈学禹,赵颖颖,施婕,孙晓茹,李秋春,何蕊言,范轶欧,迟蔚蔚. 老年人群可改变心血管危险因素聚集模式与脑卒中的关联[J]. 山东大学学报 (医学版), 2025, 63(9): 11-19.
[4]	孙爽爽,仉率杰,张伯韬,袁莹,于媛媛,薛付忠. 基于真实世界研究的18~50岁人群急性缺血性卒中影响因素[J]. 山东大学学报 (医学版), 2025, 63(9): 40-46.
[5]	万文静,高姗姗. 低分子肝素在生殖领域的应用[J]. 山东大学学报 (医学版), 2025, 63(6): 117-124.
[6]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[7]	陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[8]	孙丽娜,白红艳,牛宗格,张福帅,曲仪庆. 基于SII构建及评价预测ARDS住院死亡率的在线临床风险模型[J]. 山东大学学报 (医学版), 2024, 62(7): 10-20.
[9]	石军,牛子捷,王军,马丽晶,奚春花,肖洋. 幼年型复发性呼吸道乳头状瘤病肺部播散的临床特点及麻醉要点[J]. 山东大学学报 (医学版), 2024, 62(12): 82-89.
[10]	卢伟,刘欢,贾贤杰,苏萍,施婕,王雅倩,迟蔚蔚. 植被覆盖与呼吸系统恶性肿瘤死亡风险关联分析[J]. 山东大学学报 (医学版), 2023, 61(8): 94-100.
[11]	唐小雨,王云彦,史有奎,王敏. 肉芽肿性多血管炎继发肥厚性硬脑膜炎1例[J]. 山东大学学报 (医学版), 2023, 61(5): 122-124.
[12]	李晴,张安娜,杜艳圣,刁久洲,崔若瑾,付鹏蕊,岳欣毅,周庆博. 47例单个脊髓炎性脱髓鞘病灶转化的影响因素[J]. 山东大学学报 (医学版), 2023, 61(5): 37-43.
[13]	刘艳,冷珊珊,夏晓娜,董昊,黄陈翠,孟祥水. 基于影像组学参数评估376例幕上自发性脑出血患者的功能状态[J]. 山东大学学报 (医学版), 2023, 61(5): 59-67.
[14]	张明慧,王丽云,王芸,张新月,沙凯辉. 髋部骨折患者术后恐动症风险的列线图分析[J]. 山东大学学报 (医学版), 2023, 61(11): 74-81.
[15]	赵启迪,王凯,赵小刚,闫涛,王亚东,杜贾军. 基于SEER数据库构建并验证IIIB期非小细胞肺癌患者预后模型[J]. 山东大学学报 (医学版), 2023, 61(10): 23-37.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed